Evidence map›Paper›PMID 29771950›Full record

ArticlePloS one2018

Biophotonic detection of high order chromatin alterations in field carcinogenesis predicts risk of future hepatocellular carcinoma: A pilot study.

Richard S Kalman, Andrew Stawarz, David Nunes, Di Zhang, Mart A Dela Cruz, Arpan Mohanty, Hariharan Subramanian, Vadim Backman, Hemant K Roy

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Chromatin Organization Governs Transcriptional Response and Plasticity of Cancer Stem Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Richard S KalmanDepartment of Medicine, Einstein Medical Center, Philadelphia, Pennsylvania, United States of America.ORCID 0000-0002-2248-5032
Andrew StawarzBiomedical Engineering Department, Northwestern University, Evanston, Illinois, United States of America.
David NunesDepartment of Medicine, Boston University Medical Center, Boston, Massachusetts, United States of America.
Di ZhangBiomedical Engineering Department, Northwestern University, Evanston, Illinois, United States of America.
Mart A Dela CruzDepartment of Medicine, Boston University Medical Center, Boston, Massachusetts, United States of America.
Arpan MohantyDepartment of Medicine, Boston University Medical Center, Boston, Massachusetts, United States of America.
Hariharan SubramanianBiomedical Engineering Department, Northwestern University, Evanston, Illinois, United States of America.
Vadim BackmanBiomedical Engineering Department, Northwestern University, Evanston, Illinois, United States of America.
Hemant K RoyDepartment of Medicine, Boston University Medical Center, Boston, Massachusetts, United States of America.
Boston University · USNorthwestern University · USEinstein Medical Center Philadelphia · US

Funding

Reducing Cancer Transcriptional Heterogeneity through Regulation of Chromatin StructureR01CA228272 · NCI · NORTHWESTERN UNIVERSITY · PI BACKMAN, VADIM, ROY, HEMANT K. · 2018 to 2022
$3.2M
Risk-stratification of Prostate Cancers via Field Carcinogenesis NanocytologyR01CA200064 · NCI · NORTHWESTERN UNIVERSITY · PI BACKMAN, VADIM, CRAWFORD, SUSAN E. · 2015 to 2019
$3.1M
Nanoscale/Molecular analysis of Fecal Colonocytes for Colorectal Cancer ScreeningR01CA165309 · NCI · NORTHWESTERN UNIVERSITY · PI BACKMAN, VADIM, ROY, HEMANT K. · 2012 to 2016
$2.8M
Chemistry of Life Processes Predoctoral Training ProgramT32GM105538 · NIGMS · NORTHWESTERN UNIVERSITY · PI KELLEHER, NEIL L · 2013 to 2022
$2.7M
Nanocytological Fecal Assessment to Personalize Colonoscopic SurveillanceR42CA168055 · NCI · NANOCYTOMICS, LLC · PI ROY, HEMANT K. · 2012 to 2014
$1.8M
Area B: Minimally Intrusive Colorectal Cancer Risk Stratification with Nanocytology:Targeting Underscreened PopulationsR33CA225323 · NCI · BOSTON MEDICAL CENTER · PI BACKMAN, VADIM, ROY, HEMANT K. · 2017 to 2017
$1.6M
High-throughput molecular-specific cell nanocytology for cancer screeningR01EB016983 · NIBIB · NORTHWESTERN UNIVERSITY · PI BACKMAN, VADIM, SUBRAMANIAN, HARIHARAN · 2013 to 2016
$1.3M
NCI NIH HHS R01 CA165309NCI NIH HHS R01 CA200064NCI NIH HHS R01 CA228272NCI NIH HHS R33 CA225323NCI NIH HHS R42 CA168055NIBIB NIH HHS R01 EB016983NIGMS NIH HHS T32 GM105538
6 · The paper itself

Abstract

purposeHepatocellular carcinoma (HCC) results from chronic inflammation/cirrhosis. Unfortunately, despite use of radiological/serological screening techniques, HCC ranks as a leading cause of cancer deaths. Our group has used alterations in high order chromatin as a marker for field carcinogenesis and hence risk for a variety of cancers (including colon, lung, prostate, ovarian, esophageal). In this study we wanted to address whether these chromatin alterations occur in HCC and if it could be used for risk stratification. EXPERIMENTAL

designA case control study was performed in patients with cirrhosis who went on to develop HCC and patients with cirrhosis who did not develop cancer. We performed partial wave spectroscopic microscopy (PWS) which measures nanoscale alterations on formalin fixed deparaffinized liver biopsy specimens, 17 progressors and 26 non-progressors. Follow up was 2089 and 2892 days, respectively.

resultsPWS parameter disorder strength Ld were notably higher for the progressors (Ld = 1.47 ± 0.76) than the non-progressors (Ld = 1.00 ± 0.27) (p = 0.024). Overall, the Cohen's d effect size was 0.907 (90.7%). AUROC analysis yielded an area of 0.70. There was no evidence of confounding by gender, age, BMI, smoking status and race.

conclusionsHigh order chromatin alterations, as detected by PWS, is altered in pre-malignant hepatocytes with cirrhosis and may predict future risk of HCC.

Indexed as

AdultCarcinoma, HepatocellularCase-Control StudiesChromatinFemaleHumansLiver NeoplasmsMaleMiddle AgedPilot ProjectsRisk AssessmentChromatin

Identifiers

PMID29771950
PMCPMC5957523
OpenAlexW2803416457

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.